Wondercel Biotech (shenzhen)

This early-phase trial tests a universal (donor-derived) CAR-T cell therapy called UWD-19 for people with B-cell lymphoma or leukemia that has come back or not responded to treatment. Up to 30 participants will receive a single infusion of these cells after chemotherapy, along wi…

This early-stage study tests a new type of CAR-T cell therapy, called UWD-00B, for people with multiple myeloma that has come back or not responded to other treatments. The therapy uses donor cells that are modified to target and kill cancer cells, and does not require the patien…

This early-phase study tests a new type of immune cell therapy (universal CAR-T) in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also measuring how well the the…

This early-phase study tests a new treatment called WD-01, which uses a patient's own immune cells modified to target a protein (GCC) found on colorectal cancer cells. The goal is to see if it is safe and can shrink tumors in people with metastatic colorectal cancer who have alre…

This early-phase trial tests a new universal CAR-T cell therapy (REVO-UWD-01) in 30 adults with metastatic colorectal cancer that has spread. The treatment targets a protein called GCC found on cancer cells. The main goals are to find the safest dose and check for side effects, w…